Sanofi (SNY) has released an update.
Sanofi reports robust Q2 2024 sales growth of 10%, with high-performing Dupixent sales and successful pharma launches, despite a dip in vaccine sales compared to 2023. The company also proudly announces regulatory approvals for several drugs and an upgraded business EPS guidance for 2024, signaling stable growth prospects. These achievements underscore Sanofi’s strategic push towards becoming a leading AI-powered biopharmaceutical entity.
For further insights into SNY stock, check out TipRanks’ Stock Analysis page.
